Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Dec 17, 2018 • 4:01 PM EST
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Nov 21, 2018 • 9:00 AM EST
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Nov 8, 2018 • 8:00 AM EST
Ligand Reports Third Quarter 2018 Financial Results
Nov 8, 2018 • 9:00am EST
See all events
Nov 7, 2018 • 1:00pm EST
New York, NY
Sep 5, 2018 • 12:30pm EST
St. Regis Hotel, New York, NY
Verona Pharma initiates Phase 2 clinical trial to evaluate dry powder inhaler formulation of RPL554 for maintenance… https://t.co/fRlpHGEMtR
Syros announces new preclinical data on SY-1365 at San Antonio Breast Cancer Symposium https://t.co/mxFtgcXgFO
$APVO doses first patient in Phase 1/1b clinical trial of lead next-generation bispecific antibody APVO436 https://t.co/Gd66V3n0sL